Germany
Japan
United Kingdom
China
Recombinant Anti-CD20 (Clone 10F381 (rituximab))
| Applications | FC |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Research Areas
View as table DownloadRecombinant Anti-TNF alpha (Clone cA2 (Infliximab))
| Applications | ELISA, FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. |
USD 523.00
2 Weeks
USD 523.00
2 Weeks
Recombinant Anti-IL-2R alpha (CD25) (Clone Basiliximab)
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD41 (Clone 7E3 (Abciximab))
| Applications | FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This is a reformatted human IgG1 antibody based on the therapeutic Fab fragment. NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-CD33 (Clone hP67.6 (Gemtuzumab))
| Applications | FC, IF |
| Reactivities | Human |
| Conjugation | Unconjugated |
USD 523.00
2 Weeks
Recombinant Anti-CD4 (Clone CE9.1 (Clenoliximab))
| Applications | ELISA, FC, IHC |
| Reactivities | Chimpanzee, Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-TNF alpha (Clone D2E7 (Adalimumab))
| Applications | ELISA, IF, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-CD22 (Clone hL22 (Epratuzumab))
| Applications | Bl, FC, IP |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
Recombinant Anti-CD64 (Clone H22)
| Applications | FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-IL-6 receptor (Clone rhPM-1 (Tocilizumab))
| Applications | ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. |
Recombinant Anti-PD-L1 (Clone 332M7)
| Applications | FC |
| Reactivities | Human, Monkey, Mouse |
| Conjugation | Unconjugated |
Active filters
Filter by
Target Symbol
Reactivities
Isotypes
Conjugates
Modifications
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (5)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This is a reformatted human IgG1 antibody based on the therapeutic Fab fragment. NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (1)